Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis

American Journal of Health-System Pharmacy

Volumn 65, Issue 7, 2008, Pages 619-623

  McMahon, James H ^a   Grayson, M Lindsay ^b,c  

^a AUSTIN HEALTH   (Australia)

^b Infectious Diseases Department

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antifungals; Cryptococcosis; Dosage; Fluconazole; Flucytosine; Geriatrics; Hypokalemia; Metoprolol; Torsades de pointes; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; INDAPAMIDE; MAGNESIUM; METOPROLOL TARTRATE;

AGED; ARTICLE; BRAIN DISEASE; CASE REPORT; CEREBELLUM INJURY; CEREBRAL CRYPTOCOCCOSIS; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPONATREMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RESUSCITATION; TONIC CLONIC SEIZURE; TORSADE DES POINTES;

EID: 41749101749     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070203     Document Type: Article

References (15)

1. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004; 350:1013-22.
2. Braunwald E, Zipes D, Libby P. Heart disease. A textbook of cardiovascular medicine. 6th ed. Philadelphia: W. B. Saunders; 2001:867-70.
3. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
4. Tatetsu H, Asou N, Nakamura M et al. Torsades de pointes upon fluconazole administration in a patient with acute myeloblastic leukemia. Am J Hematol. 2006; 81:366-9.
5. Gandhi PJ, Menezes PA, Vu HT et al. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Am J Health-Syst Pharm. 2003; 60:2479-83. [Erratum, Am J Health-Syst Pharm. 2004; 61:141.]
6. Khazan M, Mathis AS. Probable case of torsades de pointes induced by fluconazole. Pharmacotherapy. 2002; 22:1632-7.
7. Tholakanahalli VN, Potti A, Hanley JF et al. Fluconazole-induced torsade de pointes. Ann Pharmacother. 2001; 35:432-4.
8. Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am J Emerg Med. 2000; 18:227-9.
9. Wassmann S, Nickenig G, Bohm M. Long QT syndrome and torsade de pointes in a patient receiving fluconazole. Ann Intern Med. 1999; 131:797. Letter.
10. Pham CP, de Feiter PW, van der Kuy PH et al. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother. 2006; 40:1456-60.
11. Kucers S, Crowe S, Grayson ML et al. The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 5th ed. Boston: Butterworth Heinemann; 1997:1385-417.
12. Dumaine R, Roy ML, Brown AM. Blockade of HERG and Kv1.5 by ketoconazole. J Pharmacol Exp Ther. 1998; 286:727-35.
13. Priori SG, Schwartz PJ, Napolitano C et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003; 348:1866-74.
14. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med. 1994; 121:529-35.
15. Al-Khatib SM, LaPointe NM, Kramer JM et al. What clinicians should know about the QT interval. JAMA. 2003; 289:2120-7. [Erratum, JAMA. 2003; 290:1318.]